The influence of COPD on mortality and severity scoring in community-acquired pneumonia

Respiration

Volumn 79, Issue 1, 2009, Pages 46-53

  Snijders, Dominic ^a   Van Der Eerden, Menno ^b   De Graaff, Casper ^a   Boersma, Wim ^a  

^a Location Alkmaar   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive lung disease; Community acquired pneumonia; CURB 65; Mortality; Pneumonia Severity Index; Severity scoring

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; GLUCOSE BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 73349086862     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000213757     Document Type: Article

References (26)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2):S27-S72.
2. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X: Epidemiology of community-acquired pneumonia in adults: A population-based study. Eur Respir J 2000; 15: 757-763.
3. LaCroix AZ, Lipson S, Miles TP, White L: Prospective study of pneumonia hospitalizations and mortality of U.S. older people: The role of chronic conditions, health behaviors, and nutritional status. Public Health Rep1989; 104: 350-360.
4. van der Eerden MM, de Graaff CS, Bronsveld W, Jansen HM, Boersma WG: Prospective evaluation of pneumonia severity index in hospitalised patients with community-acquired pneumonia. Respir Med 2004; 98: 872-878. (Pubitemid 39069337)
5. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN: Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis. JAMA 1996; 275: 134-141.
6. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
7. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L, Arevalo M, Blanquer J, Celis R, Iriberri M, Prats E, Fernandez R, Irigaray R, Serra J. Community-acquired pneumonia in chronic obstructive pulmonary disease: A Spanish multicenter study. Am J Respir Crit Care Med 1996; 154: 1456-1461
8. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A: COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28: 346-351.
9. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M: Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-1216.
10. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-248.
11. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J: Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-956.
12. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
13. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003; 58: 377-382.
14. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, Boersma WG: Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: A prospective randomised study. Thorax 2005; 60: 672-678.
15. Global Strategy for the Diagnosis, Management and Prevention of COPD. Bethesda, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2007. http://www. goldcopd.org.
16. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, Benitez Moya JM, Ruiz-Manzano J, Rodriguez de Castro F, Blanquer J, Perez D, Puzo C, Sanchez Gascon F, Gallardo J, Alvarez C, Molinos L: Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
17. Boersma WG, Sportel JH, Lowenberg A, Koeter GH: High prevalence of obstructive airways disease in hospitalised patients with community-acquired pneumonia: Comparison of four etiologies. Clin Pulm Med 2005; 12: 291-296.
18. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ: Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294: 2712-2719.
19. Lange P, Vestbo J, Nyboe J: Risk factors for death and hospitalization from pneumonia: A prospective study of a general population. Eur Respir J 1995; 8: 1694-1698.
20. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
21. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y: Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis. BMJ 2004; 329: 480.
22. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW: Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: A randomized controlled study. Chest 1993; 104: 389-392.
23. McHardy VU, Schonell ME: Ampicillin dosage and use of prednisolone in treatment of pneumonia: Co-operative controlled trial. Br Med J 1972; 4: 569-573.
24. Salluh JI, Verdeal JC, Mello GW, Araujo LV, Martins GA, de Sousa Santino M, Soares M: Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 2006; 32: 595-598.
25. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P: Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174: 1319-1326.
26. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, Moritz F, Cibien JF, Guerin T, Carre E, Lafontaine A, Bertrand MP, Santin A, Brun-Buisson C, Fine MJ, Roupie E; Pneumocom Study Investigators: Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: A multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007; 44: 41-49.